Sonazoid CEUS for Early HCC Surveillance
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorTianjin Third Central Hospital
About this trial
This study is a multicenter, prospective study. In this study, enrolled subjects are cirrhotic patients of any etiology. The US and Sonazoid CEUS monitoring strategy was performed for cirrhotic patients: US and AFP joint with Sonazoid CEUS every 4 to 6 months, and combined CECT/CEMRI every 12 months.
Eligibility criteria
Qualifiers
Cirrhotic patients diagnosed clinically or radiologically due to any etiology (patients with cirrhosis due to congenital fibrosis and patients with cirrhosis due to vascular causes were excluded).
Age 18-80 years old.
Able to receive regular imaging, including US, CEUS, and CECT or CEMRI or EOB-MRI, according to the diagnostic and treatment procedures.
Obtained informed consent from the patient.
Disqualifiers
Patients with pathologic or enhanced imaging of established HCC who have not undergone curative treatment.
Patients with known hypersensitivity to enhanced imaging contrast agents.
Patients with severe cardiac, pulmonary or renal insufficiency that precludes CECT or CEMRI or EOB-MRI.
Lactating and pregnant women.
Trial design
Treatments tested in this trial
- Sonazoid CEUS
Treatment groups
556 Participants
are divided into 1 treatment groupLocations
1Tianjin Third Central Hospital300170, TianjinTianjin Municipality, China
Sponsors and collaborators
Tianjin Third Central Hospital
Lead sponsor
Source ClinicalTrials.gov